---
title: "Peptides for Anxiety: Selank, Semax and the Russian Trial Literature"
canonical_url: https://peptidelibrary.app/blog/peptides-for-anxiety
description: "These compounds have real clinical trials behind them, in a literature most Western readers cannot access or appraise."
updated: 2026-10-28
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Peptides for Anxiety: Selank, Semax and the Russian Trial Literature

These compounds have real clinical trials behind them, in a literature most Western readers cannot access or appraise.

**Selank and semax occupy an unusual position. **Unlike most research peptides they have been through clinical trials in humans, are registered medicines in Russia, and have published efficacy data — almost all of it in Russian-language journals.

That combination makes them harder to assess than compounds with no evidence at all, because the evidence exists and is difficult for most readers to appraise.

## Selank

Selank is a synthetic analogue of tuftsin, a naturally occurring immunomodulatory peptide, with a sequence modification intended to extend its stability.

The published clinical work includes:

- **A 2008 study **examining efficacy and possible mechanisms in generalised anxiety disorder and neurasthenia.
- **A 2014 comparison against phenazepam, **a benzodiazepine, assessing both anxiolytic effect and tolerability.
- **A 2015 study **on optimising treatment of anxiety disorders with selank.

> **The phenazepam comparison is the most informative of these. **An active comparator design against an established benzodiazepine is a considerably stronger test than placebo alone — it asks whether the compound is competitive with something known to work, which is the question that matters clinically.

## How to weigh the Russian literature

Dismissing this evidence outright is not justified, and accepting it uncritically is not either. The specific limitations are worth naming:

| **Consideration** | **Detail** |
| --- | --- |
| Language | Most publications are Russian-only; abstracts alone are thin |
| Trial registration | Prospective registration is less consistently applied |
| Sample sizes | Generally small by Western regulatory standards |
| Replication | Little independent replication outside Russia |
| Regulatory review | Registered in Russia; no FDA or EMA review |
| Publication bias | Difficult to assess without a registry to compare against |

**The honest summary: this is real clinical research that has not been independently replicated or reviewed by a Western regulator. **It sits above "rodent studies only" and below "approved drug", and there is no shorthand for that position.

## Semax

Semax is an analogue of ACTH(4-10), modified so that it lacks the hormonal activity of the parent fragment. A 2006 Brain Research paper found that semax regulates BDNF and trkB expression in the rat hippocampus — a plausible and specific mechanism, since BDNF signalling is implicated in both mood and cognition.

**Semax is more often positioned for cognition than for anxiety, **and the two compounds are frequently confused. See [semax vs selank](https://peptidelibrary.app/blog/semax-vs-selank) for the distinction.

## The nasal route

Both are commonly supplied as nasal sprays rather than for injection, which is unusual in this market and is a deliberate design feature rather than a convenience.

- **Intranasal administration **is proposed to allow some access to the central nervous system.
- **Both are small peptides, **which is relevant to whether that route is plausible at all.
- **Bioavailability by this route is not well characterised **for either compound in the accessible literature.
- **Concentration and delivered volume vary between preparations, **so "sprays" is not a dose. The [peptide calculator](https://peptidelibrary.app/calculator) does not help here, because the delivered volume per actuation is a property of the device.

## Status

|  | **Selank** | **Semax** |
| --- | --- | --- |
| US approval | None | None |
| Russian registration | Yes | Yes |
| Human trials | Yes — anxiety disorders | Yes — cognitive and neurological |
| Independent Western replication | No | No |
| Sold in the US as | Research compound | Research compound |

> **Registration in Russia does not transfer. **It means a regulator reviewed a dossier under its own standards — not that FDA or EMA would reach the same conclusion, and not that the material sold in the US resembles the registered product. A batch-specific COA is the only thing establishing what is in a given vial.

## What anxiety treatment has stronger evidence for

Anxiety disorders are among the best-studied conditions in medicine, and the interventions with large, replicated, independently reviewed trial evidence are:

1. **Cognitive behavioural therapy **— comparable to medication in effect size for many anxiety disorders, without pharmacological risk.
2. **SSRIs and SNRIs **— first-line pharmacotherapy with extensive evidence.
3. **Buspirone **for generalised anxiety.
4. **Exercise **— consistent, moderate effects across trials.
5. **Sleep and alcohol assessment, **since both are common and modifiable contributors.

> **Anxiety that is persistent or impairing is a clinical problem with effective treatments. **The compounds on this page have less evidence than any option in that list, and self-treating a psychiatric condition with an unapproved compound delays access to things that reliably work.

See the [selank dosage guide](https://peptidelibrary.app/blog/selank-dosage) and the [semax benefits guide](https://peptidelibrary.app/blog/semax-benefits).

> **Research and educational use only. **Peptide Library is an independent research and comparison platform and does not sell peptides. Nothing here is medical advice, dosing guidance, or a recommendation to administer any substance to a person or an animal. Consult a licensed clinician for anything concerning human health.

## Sources

- [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders](https://pubmed.ncbi.nlm.nih.gov/25176261/)
- [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia](https://pubmed.ncbi.nlm.nih.gov/18454096/)
- [Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus](https://pubmed.ncbi.nlm.nih.gov/16996037/)